AstraZeneca PLC (AZNCF)
| Market Cap | 266.28B |
| Revenue (ttm) | 56.50B |
| Net Income (ttm) | 8.30B |
| Shares Out | n/a |
| EPS (ttm) | 5.31 |
| PE Ratio | 32.10 |
| Forward PE | 17.63 |
| Dividend | 3.13 (1.82%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 2 |
| Average Volume | 4,507 |
| Open | 173.00 |
| Previous Close | 172.10 |
| Day's Range | 169.85 - 173.00 |
| 52-Week Range | 120.64 - 175.00 |
| Beta | 0.17 |
| RSI | 62.93 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
Collaboration Between Turbine and AstraZeneca (AZN) Enhances ADC Discovery
Collaboration Between Turbine and AstraZeneca (AZN) Enhances ADC Discovery
AstraZeneca (AZN) Unaffected by Potential Tariffs on Generic Drugs
AstraZeneca (AZN) Unaffected by Potential Tariffs on Generic Drugs
Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery
LONDON, UK and BUDAPEST, HUNGARY , Oct. 9, 2025 /PRNewswire/ -- Turbine, a leading company specializing in virtualizing biological experiments with AI, today announced a collaboration with AstraZeneca...
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
AZN's baxdrostat hit the main goal in the phase III Bax24 study, showing significant blood pressure reductions in patients with resistant hypertension.
AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial
AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial
AZN: Baxdrostat Shows Promising Results in Phase III Trial
AZN: Baxdrostat Shows Promising Results in Phase III Trial
AstraZeneca succeeds in late-stage trial for blood pressure therapy
Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in a...
AZN : Baxdrostat Meets Primary Endpoint In Phase III Trial For Treatment-Resistant Hypertension
(RTTNews) - AstraZeneca (AZN, AZN.L,ZEG.DE,AZN.ST) announced that baxdrostat met the primary endpoint in the Bax24 Phase III trial, demonstrating a statistically significant and clinically meaningful ...
AstraZeneca's Baxdrostat meets main goal in high blood pressure study
AstraZeneca said on Tuesday its drug Baxdrostat met the main goal in a late-stage study in patients with treatment-resistant high blood pressure, or hypertension.
AstraZeneca (AZN) Signs $555 Million AI Agreement with Algen to Develop Therapies
AstraZeneca (AZN) Signs $555 Million AI Agreement with Algen to Develop Therapies
AstraZeneca (AZN) Achieves Key Milestones in Breast Cancer Treatment Study
AstraZeneca (AZN) Achieves Key Milestones in Breast Cancer Treatment Study
AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases
Algen Biotechnologies , a privately held biotech company specializing in advanced CRISPR gene modulation and AI-driven drug discovery, has announced a multi-target partnership with AstraZeneca Plc (NA...
AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study
AstraZeneca & Daiichi Sankyo's Datroway shows improved survival in late-stage triple-negative breast cancer trial. Read more here.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies
Algen Biotechnologies said on Monday it has agreed to grant AstraZeneca a license to develop gene therapies the U.S.-based biotech discovers using its artificial intelligence-driven platform, in a dea...
Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca
SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca.
DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02
DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom immuno...
AstraZeneca Reaches Analyst Target Price
In recent trading, shares of AstraZeneca plc (Symbol: AZN) have crossed above the average analyst 12-month target price of $85.09, changing hands for $85.31/share. When a stock reaches the target an a...
AZN: Promising Phase 3 Trial Results for Breast Cancer Treatment
AZN: Promising Phase 3 Trial Results for Breast Cancer Treatment
AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports
AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday.
AstraZeneca's Datroway boosts survival in advanced breast cancer trial
AstraZeneca said on Monday its precision drug Datroway improved overall survival and progression free survival in patients with an advanced form of breast cancer versus chemotherapy in a trial when gi...
Astrazeneca (AZN) Rises Higher Than Market: Key Facts
Astrazeneca (AZN) closed at $85.31 in the latest trading session, marking a +1.98% move from the prior day.
Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated
Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, e...
AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy?
The uncertainty about U.S. pharmaceutical tariffs shouldn't be as worrisome for AstraZeneca now.